BubbForest 40:1 Myo‑Inositol & D‑Chiro‑Inositol, 2010 mg, 120 Capsules

Understanding the 40:1 ratio

The ratio describes the relative quantities of myo-inositol and D-chiro-inositol. It does not specify the daily dose or guarantee an outcome. Dividing the label’s 2,008 mg by 50 mg gives 40.16:1, rounded to approximately 40:1. Together, the two inositols provide 2,058 mg per four-capsule serving.

Label clarification: The product name currently states 2,010 mg, while the displayed ingredient panel states 2,008 mg myo-inositol. The detailed amounts below follow that panel. Compare these with the physical bottle supplied to you; contact BubbForest if your label differs.

Featured branded ingredient

Curcugen®: the turmeric matrix makes a difference

BubbForest’s four-capsule serving includes 64 mg of the turmeric extract identified on its label as Curcugen® Liposomal (SELF-D™ self-dispersion platform), equivalent to 1,600 mg dry turmeric rhizome. Understanding the underlying ingredient technology adds context beyond the extract’s weight.

How it differs from conventional C-95 extracts

DolCas describes Curcugen® as a turmeric-oleoresin ingredient that retains curcuminoids together with native essential oils and polar resins. Its SELF-D approach uses these naturally occurring constituents to promote dispersion in water. In contrast, conventional C-95 is standardized to 95% curcuminoids. Curcugen’s manufacturer describes a 50% curcuminoid standard within a broader turmeric matrix. A higher curcuminoid percentage alone does not establish better absorption. [4]

Proprietary technology and patent protection

DolCas states that the process used to preserve Curcugen’s full-spectrum profile is patent-protected. This is the supplier’s description of its ingredient technology, not a patent belonging to BubbForest. Curcugen® is a registered trademark of DolCas Biotech, LLC. [4]

What “39×” and “52.5×” refer to

The supplier’s 2025 technical overview reports 39-fold greater free-curcumin bioavailability and 52.5-fold greater total-curcuminoid bioavailability versus C-95 in the cited absorption study. These are different measurements, not interchangeable claims. They do not mean that this BubbForest product is 52.5 times more effective, and they do not establish the same absorption advantage at this formula’s 64 mg serving.

Human studies: keep the dose in view

The supplied overview summarizes ingredient trials in exercise recovery (24 participants; 500 mg/day), gut and mood health (80 participants; 500 mg/day), and knee joint health (100 participants; 1,000 mg/day). These study doses exceed the 64 mg extract amount in this formula’s four-capsule serving. Their results cannot be transferred directly to this combined inositol product, and are not a reason to increase its dose.

A note on the term “liposomal”

The current BubbForest ingredient panel uses “Curcugen® Liposomal.” The supplier overview and public technology description explain a turmeric oleoresin matrix and self-dispersion; they do not establish a conventional phospholipid-bilayer liposome structure. The ingredient should therefore be understood through its documented matrix and dispersion technology, without assuming equivalence to other liposomal formulations.

Technical context: DolCas Biotech Curcugen® supplier overview, © 2025, supplied to BubbForest; and the manufacturer’s public ingredient page. The additional patent dossier identifies US 12,208,129 B2, granted 28 January 2025 to Olene Life Sciences Private Limited. See the ingredient documentation for its scope.

What human research tells us

Inositol and PCOS research

A systematic review informing the 2023 international PCOS guideline included 30 trials involving 2,230 participants. Some metabolic measures showed possible improvements, but the overall evidence was limited and inconclusive. Results varied across formulations and outcomes. These studies do not establish that this finished BubbForest formula treats PCOS or reliably changes menstrual cycles. [1]

Why an individual approach matters

The 2023 guideline allows consideration of inositol according to individual preferences, while noting limited clinical benefits and insufficient evidence to recommend a specific type, dose or combination. Its use for PCOS-related infertility remains experimental, with uncertain pregnancy and live-birth outcomes. Discuss persistent cycle changes or fertility concerns with a qualified clinician. [2]

Turmeric in context

The botanical extract is part of this formula, but research on turmeric does not establish broad health benefits or prove the effectiveness of this combination. NCCIH also notes liver-injury reports with some enhanced-absorption curcumin products. [3]

Frequently asked questions

Are the amounts per capsule?

No. All amounts in the table are for four capsules.

Is this the same as the 90-capsule formula?

This page describes the 120-capsule version and its own ingredient panel. Do not assume that serving sizes or ingredient amounts are interchangeable.

Will it balance hormones or improve fertility?

Those outcomes cannot be promised. Ingredient-level research is not proof of a clinical outcome for this finished formula.

How long will one bottle last?

There are 30 four-capsule servings. At one such serving per day, the bottle would last 30 days; use only the schedule directed on your bottle or by your clinician.